Founded in 2018, ImmunoACT operates in Health Tech offering gene-modified cell therapies, specifically CAR-T cell therapy for treating certain B-cell malignancies. The company was spun out from IIT-Bo...
Funding stage:
Corporate Round
Last funding:
30/05/2023
Total funding:
$17.18 Mn+
Revenue:
Investors
Employee count:
192
Last 90d
192
Last 90d
Web traffic:
3.51K
3.51K
Last 30d
Last 30d
Glassdoor Rating:
ImmunoACT: Cap Table Highlights
A snapshot of cap table and shareholder metrics
Total Shareholders18
Latest Filing Date04 April 2024- Funding Events15
Event-Based View
Event-Based detailed View by Filings
FAQs on Cap Table of ImmunoACT
As of 05 April 2024, ImmunoACT's equity is held by 17 shareholders, with the top three being Laurus Labs Limited, Rahul Purwar, and Shalini Purwar.
Laurus Labs Limited holds the largest stake in ImmunoACT at 33.8% as of 05 April 2024.
As of 05 April 2024, founders collectively hold 31.4% equity in ImmunoACT.
As of 05 April 2024, investors collectively hold 41.7% equity in ImmunoACT.
ImmunoACT's ESOP pool stands at 3.1% of total equity as of 05 April 2024.
Disclaimer
Inc42 Datalabs consolidates intelligence from public records, statutory filings, proprietary research, and vetted third‑party datasets. All information is provided as is—please run your own checks before acting on it. Inc42 Datalabs bears no responsibility for decisions or outcomes based on this data.
Quick Links